Detalhe da pesquisa
1.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Clin Cancer Res
; 14(5): 1464-9, 2008 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18316570